Nexium Control 28 Tablet Pack

Go To

Improved value and convenience
Why recommend Nexium Control?
Recommend for patients with frequent heartburn
Nexium Control Product Information

Improved value & convenience for patients with recurrent frequent heartburn

Exclusive to pharmacy, the new Nexium Control pack size, 28 tablets, offers benefits for patients who have used esomeprazole with positive results:

Improved value at a lower cost per tablet
Product available on hand for future episodes
Meets the shopper needs for larger packs¹

Access educational resources to support the recommendation of Nexium 28 tablet pack.

Understanding frequency is key to an appropriate recommendation

Ask patients how often they suffer – more than once a week is classed as frequent heartburn
Patients with frequent heartburn may benefit from a PPI such as Nexium Control to give the oesophagus a ‘holiday’ from acid and reduce sensitivity

Learn more about the role of frequency in heartburn treatment recommendations.

Recommend Nexium Control to patients with heartburn more than once per week

Nexium Control 28 tablet pack

For patients with recurrent frequent heartburn who have used esomeprazole successfully and seek the value and convenience of a larger pack.

Nexium Control 7 and 14 tablet packs

Nexium Control 7 tablet pack is an ideal trial pack with one-week supply. Nexium Control 14 tablet pack offers the same protection and offers a 2-week treatment. 2-3 consecutive days treatment may be needed to achieve improvement of symptoms. The duration of treatment is up to 2 weeks. Once complete relief of symptoms has occurred, treatment should be discontinued.

If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor.

Nexium Control 14 Capsule pack

Easy-to swallow mini capsules – 53% smaller than tablet* in a portable bottle. Complete 14-day treatment. 2-3 consecutive days treatment may be needed to achieve improvement of symptoms. The duration of treatment is up to 2 weeks. Once complete relief of symptoms has occurred, treatment should be discontinued.

If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor.

*based on volume

Nexium Control Product Information

Product Information

Full information can be found in the Summary of Product Characteristics.

Nexium Control 20 mg gastro-resistant tablets and Nexium Control 20 mg gastro-resistant hard capsules (Esomeprazole). Indications: The short-term treatment of reflux symptoms (e.g., heartburn and acid regurgitation) in adults. Dosage: The recommended dose is 20 mg (one tablet or capsule) per day. Tablets or capsules may need to be taken for 2-3 consecutive days to achieve symptom improvement. Maximum treatment duration: up to 2 weeks. Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients. Esomeprazole must not be used concomitantly with nelfinavir. Warnings and precautions: Patients should consult a doctor if: They have significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded to avoid delay in diagnosis. Also, if they have had previous gastric ulcer or gastrointestinal surgery, been on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks, have jaundice or severe liver disease, are aged over 55 years with new or recently changed symptoms. Long-term recurrent symptoms of indigestion or heartburn require regular doctor consultation and those over 55 years taking any non-prescription indigestion or heartburn remedy daily should inform their pharmacist or doctor. Nexium Control should not be taken as a long-term preventive product. Treatment with PPIs may lead to a slightly increased risk of GI infections such as Salmonella and Campylobacter and in hospitalised patients, possibly Clostridium difficile. Patients should consult their doctor before taking this medicinal product if they are due to have an endoscopy or urea breath test. Co-administration of esomeprazole with atazanavir is not recommended. The potential for interactions with medicinal products metabolised through CYP2C19 should be considered. Concomitant use with clopidogrel is discouraged. Not to be taken with another PPI or H₂ antagonist. Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. PPIs are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE). If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, medical help should be sought promptly, and discontinuation considered. SCLE after previous treatment with a PPI may increase the risk of SCLE with other PPIs. Contains sugar spheres (sucrose). Not suitable for patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency. Side effects: Refer to the SPC for full details. Common: headache and GI disorders, including abdominal pain, constipation, diarrhoea, and nausea/vomiting, fundic gland polyps (benign). Uncommon: peripheral oedema, insomnia, dizziness, paraesthesia, somnolence, vertigo, dry mouth, increased liver enzymes, dermatitis, pruritus, rash and urticaria. Legal category: GSL (7s and 14s) and P (28s). Product licence number: GSL: Capsules PLGB 44673/0221 & Tablets PLGB 44673/0222, P: Tablets PLGB 44673/0225. MAH: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, U.K. RRP (excl VAT): Tablets: 7s £5.99, 14s £10.39, 28s £20.42. Capsules: 14s £11.19. Text prepared: Feb 2025